gms | German Medical Science

Frühjahrstagung der Sektion Antimykotische Chemotherapie 2014

Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG e. V.)

23. - 24.05.2014, Bonn

Article

Send article

Bronchoalveolar Lavage Lateral-Flow Device Test For Invasive Pulmonary Aspergillosis In Patients With Hematologic Malignancies And In Solid Organ Transplant Patients: A Multicenter Study

Meeting Abstract

Search Medline for

  • corresponding author S. Eigl - Section of Infectious Diseases and Tropical medicine, Medical University of Graz, Graz, Austria
  • D. Buchheidt - Department of Hemato/Oncology, University Hospital of Mannheim, Mannheim, Germany
  • B. Willinger - Division of Clinical Microbiology, Medical University of Vienna, Vienna, Austria
  • J. Prattes - Section of Infectious Diseases and Tropical medicine, Medical University of Graz, Graz, Austria
  • M. Lackner - Institute of Hygiene and Microbiology, Medical University of Innsbruck, Innsbruck, Austria
  • W. Duettmann - Division of Hematology, Medical University of Graz, Graz, Austria
  • V. Posch - Section of Infectious Diseases and Tropical medicine, Medical University of Graz, Graz, Austria
  • B. Spiess - Department of Hemato/Oncology, University Hospital of Mannheim, Mannheim, Germany
  • R. Krause - Section of Infectious Diseases and Tropical medicine, Medical University of Graz, Graz, Austria
  • C. Lass-Flörl - Institute of Hygiene and Microbiology, Medical University of Innsbruck, Innsbruck, Austria
  • B. Selitsch - Division of Clinical Microbiology, Medical University of Vienna, Vienna, Austria
  • S. Eschertzhuber - Medical University of Anaethesia and Intensive Care, Medical University of Innsbruck, Innsbruck, Austria
  • K. Hönigl - Section of Infectious Diseases and Tropical medicine, Medical University of Graz, Graz, Austria
  • C. Koidl - Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria
  • M. Sereinigg - Division of Transplant Surgery, Medical University of Graz, Graz, Austria
  • R. B. Raggam - Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
  • C.R. Thornton - Biosciences, University of Exeter, Exeter, United Kingdom
  • M. Hoenigl - Section of Infectious Diseases and Tropical medicine, Medical University of Graz, Graz, Austria

Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG). Frühjahrstagung der Sektion Antimykotische Chemotherapie 2014. Bonn, 23.-24.05.2014. Düsseldorf: German Medical Science GMS Publishing House; 2014. Doc14sac10

doi: 10.3205/14sac10, urn:nbn:de:0183-14sac105

Published: May 19, 2014

© 2014 Eigl et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Timely diagnosis and early intervention with antifungal drugs are key factors in the successful treatment of invasive pulmonary aspergillosis (IPA). Therefore, new diagnostic tests are urgently needed. The Lateral-Flow Device (LFD) test is a rapid (15 min) single sample point-of-care test that is based on the detection of an Aspergillus extracellular glycoprotein antigen by monoclonal antibody JF5. In a multicenter study we evaluated the LFD test by using bronchoalveolar lavage (BAL) samples from patients after solid organ transplantation (SOT) and from patients with hematologic malignancies.

47 BAL samples from 47 SOT patients (11 probable/proven IPA, 11 possible IPA, 25 no IPA) and 74 BAL samples from 74 patients with underlying hematological malignancies (30 probable/proven IPA) were included. Diagnostic accuracy of LFD for probable/proven IPA was evaluated. Participating centers were the three Austrian Medical Universities of Innsbruck, Vienna and Graz and the University Hospital of Mannheim, Germany.

Sensitivity and specificity, positive- and negative predictive value as well as diagnostic odds ratio of BAL LFD tests for probable IPA in patients with SOT and those with hematologic malignancies are depicted in Table 1 [Tab. 1].

To conclude, the LFD test of BAL specimens is performed easily and provides accurate and rapidly available results in patients after SOT as well as in patients with underlying hemato-oncological malignancies. Therefore, this new point-of-care test may be a very promising diagnostic approach for detecting IPA using BAL specimens.